---
title: 'Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic
  disease-modifying antirheumatic drugs stand today?'
date: '2023-07-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37493758/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230726180750&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Biologics and Janus kinase (JAK) inhibitors play an important role in
  the treatment of rheumatoid arthritis. As new therapeutic developments have emerged
  in recent decades, the morbidity and mortality of rheumatoid arthritis have been
  significantly reduced. The characterization of the structure and function of immune
  cell receptors has led to the development of biologics that specifically inhibit
  cytokines and immune cell receptors. An important therapeutic addition was the approval
  of ...
disable_comments: true
---
Biologics and Janus kinase (JAK) inhibitors play an important role in the treatment of rheumatoid arthritis. As new therapeutic developments have emerged in recent decades, the morbidity and mortality of rheumatoid arthritis have been significantly reduced. The characterization of the structure and function of immune cell receptors has led to the development of biologics that specifically inhibit cytokines and immune cell receptors. An important therapeutic addition was the approval of ...